FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893070412> ?p ?o ?g. }

• W2893070412 abstract "Due to limitations of conventional medicine for atopic eczema (AE), complementary and alternative medicine (CAM) is widely used as an alternative, maintaining, or simultaneous treatment for AE. We aimed to evaluate the beneficial and harmful effects of CAM for children with AE under 14 years old.We searched for randomized trials on CAM in 12 Chinese and English databases from their inception to May 2018. We included children (< 14 years) diagnosed with AE, who received CAM therapy alone or combined with conventional medicine. We extracted data, and used the Cochrane Risk of bias tool to assess methodological quality. Effect was presented as relative risk (RR) or mean difference (MD) with 95% confidence interval (CI) using RevMan 5.3.Twenty-four randomized controlled trials involving 2233 children with AE were included. Methodological quality was of unclear or high risk of bias in general. The trials tested 5 different types of CAM therapies, including probiotics, diet, biofilm, borage oil, and swimming. Compared to placebo, probiotics showed improved effect for the SCORAD index (MD 9.01, 95% CI 7.12-10.90; n = 5). For symptoms and signs such as itching, skin lesions, CAM combined with usual care was more effective for symptom relief ≥95% (RR 1.47, 95% CI 1.30-1.68; n = 8), and for ≥50% symptoms improvement (RR 1.34, 1.25-1.45; n = 9) compared to usual care. There was no statistic significant difference between CAM and usual care on ≥95% improvement or ≥ 50% improvement of symptoms. However, swimming, diet and biofilm showed improvement of clinical symptoms compared with usual care. At follow-up of 8 weeks to 3 years, CAM alone or combined with usual care showed lower relapse rate (RR 0.38, 0.28-0.51, n = 2; RR 0.31, 0.24-0.40, n = 7; respectively) compared to usual care. Twelve out of 24 trials reported no occurrence of severe adverse events.Low evidence demonstrates that some CAM modalities may improve symptoms of childhood AE and reduce relapse rate. Safety remains unclear due to insufficient reporting. Further well-designed randomized trials are needed to confirm the potential beneficial effect and to establish safety use." @default.
• W2893070412 created "2018-10-05" @default.
• W2893070412 creator A5006126829 @default.
• W2893070412 creator A5014155081 @default.
• W2893070412 creator A5021835267 @default.
• W2893070412 creator A5028536689 @default.
• W2893070412 creator A5035981893 @default.
• W2893070412 creator A5039382469 @default.
• W2893070412 creator A5042768833 @default.
• W2893070412 creator A5058071405 @default.
• W2893070412 creator A5069078727 @default.
• W2893070412 creator A5091395390 @default.
• W2893070412 creator A5091757432 @default.
• W2893070412 date "2018-09-26" @default.
• W2893070412 modified "2023-10-08" @default.
• W2893070412 title "Complementary and alternative medicine for treatment of atopic eczema in children under 14 years old: a systematic review and meta-analysis of randomized controlled trials" @default.
• W2893070412 cites W1527957830 @default.
• W2893070412 cites W1534789916 @default.
• W2893070412 cites W1542160655 @default.
• W2893070412 cites W1544448585 @default.
• W2893070412 cites W1557899177 @default.
• W2893070412 cites W1723492156 @default.
• W2893070412 cites W1852007369 @default.
• W2893070412 cites W1904408243 @default.
• W2893070412 cites W1987625243 @default.
• W2893070412 cites W1992256594 @default.
• W2893070412 cites W2019160240 @default.
• W2893070412 cites W2031396947 @default.
• W2893070412 cites W2037641643 @default.
• W2893070412 cites W2054027631 @default.
• W2893070412 cites W2060956173 @default.
• W2893070412 cites W2061150514 @default.
• W2893070412 cites W2078983184 @default.
• W2893070412 cites W2115952980 @default.
• W2893070412 cites W2120246175 @default.
• W2893070412 cites W2120960063 @default.
• W2893070412 cites W2136137437 @default.
• W2893070412 cites W2136530100 @default.
• W2893070412 cites W2145297425 @default.
• W2893070412 cites W2150513168 @default.
• W2893070412 cites W2156098321 @default.
• W2893070412 cites W2169895371 @default.
• W2893070412 cites W2170624839 @default.
• W2893070412 cites W2174470399 @default.
• W2893070412 cites W2178847166 @default.
• W2893070412 cites W2308566765 @default.
• W2893070412 cites W246286872 @default.
• W2893070412 cites W2571477237 @default.
• W2893070412 cites W4294215472 @default.
• W2893070412 doi "https://doi.org/10.1186/s12906-018-2306-6" @default.
• W2893070412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6332624" @default.
• W2893070412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30642310" @default.
• W2893070412 hasPublicationYear "2018" @default.
• W2893070412 type Work @default.
• W2893070412 sameAs 2893070412 @default.
• W2893070412 citedByCount "19" @default.
• W2893070412 countsByYear W28930704122019 @default.
• W2893070412 countsByYear W28930704122020 @default.
• W2893070412 countsByYear W28930704122021 @default.
• W2893070412 countsByYear W28930704122022 @default.
• W2893070412 countsByYear W28930704122023 @default.
• W2893070412 crossrefType "journal-article" @default.
• W2893070412 hasAuthorship W2893070412A5006126829 @default.
• W2893070412 hasAuthorship W2893070412A5014155081 @default.
• W2893070412 hasAuthorship W2893070412A5021835267 @default.
• W2893070412 hasAuthorship W2893070412A5028536689 @default.
• W2893070412 hasAuthorship W2893070412A5035981893 @default.
• W2893070412 hasAuthorship W2893070412A5039382469 @default.
• W2893070412 hasAuthorship W2893070412A5042768833 @default.
• W2893070412 hasAuthorship W2893070412A5058071405 @default.
• W2893070412 hasAuthorship W2893070412A5069078727 @default.
• W2893070412 hasAuthorship W2893070412A5091395390 @default.
• W2893070412 hasAuthorship W2893070412A5091757432 @default.
• W2893070412 hasBestOaLocation W28930704121 @default.
• W2893070412 hasConcept C126322002 @default.
• W2893070412 hasConcept C141071460 @default.
• W2893070412 hasConcept C142724271 @default.
• W2893070412 hasConcept C168563851 @default.
• W2893070412 hasConcept C17744445 @default.
• W2893070412 hasConcept C1862650 @default.
• W2893070412 hasConcept C199539241 @default.
• W2893070412 hasConcept C204787440 @default.
• W2893070412 hasConcept C27081682 @default.
• W2893070412 hasConcept C2776173921 @default.
• W2893070412 hasConcept C2776478404 @default.
• W2893070412 hasConcept C2779134260 @default.
• W2893070412 hasConcept C2779473830 @default.
• W2893070412 hasConcept C2779923671 @default.
• W2893070412 hasConcept C2780501606 @default.
• W2893070412 hasConcept C44249647 @default.
• W2893070412 hasConcept C71924100 @default.
• W2893070412 hasConcept C82789193 @default.
• W2893070412 hasConcept C95190672 @default.
• W2893070412 hasConceptScore W2893070412C126322002 @default.
• W2893070412 hasConceptScore W2893070412C141071460 @default.
• W2893070412 hasConceptScore W2893070412C142724271 @default.
• W2893070412 hasConceptScore W2893070412C168563851 @default.
• W2893070412 hasConceptScore W2893070412C17744445 @default.
• W2893070412 hasConceptScore W2893070412C1862650 @default.
• W2893070412 hasConceptScore W2893070412C199539241 @default.

• next